Company Announcements

Total Voting Rights Update

Source: RNS
RNS Number : 5313J
Shield Therapeutics PLC
29 April 2022

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")


Total Voting Rights Update


London, UK, 29 April 2022: Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 216,192,462 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.


The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.


For further information please contact:


Shield Therapeutics plc

Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO


Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Christopher Golden

+44 (0)20 7418 8900


Joint Broker

finnCap Ltd     

Geoff Nash/Alice Lane/George Dollemore                                            




+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR (UK Advisor)

Paul McManus/Lianne Applegarth/Alice Woodings


Investor Contact (US Advisor)

+44 (0)20 7933 8780 or

LifeSci Advisors, LLC

John Mullaly



+1 617 429 3548 or


About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.


Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.


For more information, please visit Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.